Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
SingHealth Duke-NUS Transplant Centre, Singapore, Singapore.
Int J Immunogenet. 2023 Dec;50(6):306-315. doi: 10.1111/iji.12639. Epub 2023 Sep 30.
Human leucocyte antigen (HLA) alleles may generate antibodies that are undetectable by routine single-antigen beads (SABs) assays if their unique epitopes are unrepresented. We aimed to describe the prevalence and explore the potential impact of unrepresented HLA alleles in standard SAB kits in our cohort. All individuals who had undergone two-field HLA typing (HLA-A/B/C/DRB1/DQA1/-DQB1/-DPA1/-DPB1) from February 2021 to July 2023 were included. Two-field HLA-DRB3/4/5 typing was imputed. Each unrepresented allele was compared with the most similar represented allele in the standard LABScreen, LABScreen ExPlex (One Lambda) and the LIFECODES (Immucor) SAB kits. Differences in eplet expression (HLA Eplet Registry) were identified. Differences in three-dimensional molecular structures were visualized using generated models (SWISS-MODEL). Two-field HLA typing was performed for 116 individuals. Overall, 16.7% of all HLA alleles, found in 36.2% of individuals, were unrepresented by all SAB test kits. Four eplets, found in 12.9% of individuals, were unrepresented in at least 1 SAB kit. Non-Chinese individuals were more likely to have unrepresented HLA alleles and eplets than Chinese individuals. There were differences in HLA allele and eplet representation amongst the different SAB test kits. Use of supplementary SAB test kits may improve HLA allele and eplet representation. Although some HLA alleles were unrepresented, most epitopes were represented in current SAB kits. However, some unrepresented alleles may contain epitopes which may generate undetectable antibodies. Further studies may be needed to investigate the potential clinical impact of these unrepresented alleles and eplets, especially in certain ethnic populations or at-risk individuals.
人类白细胞抗原 (HLA) 等位基因可能会产生无法通过常规单抗原珠 (SAB) 检测到的抗体,如果它们独特的表位未被代表。我们旨在描述在我们的队列中标准 SAB 试剂盒中未被代表的 HLA 等位基因的流行情况,并探讨其潜在影响。所有在 2021 年 2 月至 2023 年 7 月期间进行过两区域 HLA 分型 (HLA-A/B/C/DRB1/DQA1/-DQB1/-DPA1/-DPB1) 的个体均被纳入研究。两区域 HLA-DRB3/4/5 分型被推断。将每个未被代表的等位基因与标准 LABScreen、LABScreen ExPlex(One Lambda)和 LIFECODES(Immucor)SAB 试剂盒中的最相似代表等位基因进行比较。鉴定了 eplet 表达的差异(HLA Eplet Registry)。使用生成的模型(SWISS-MODEL)可视化三维分子结构的差异。对 116 个人进行了两区域 HLA 分型。总体而言,所有 SAB 测试试剂盒中未代表的所有 HLA 等位基因占 16.7%,发现于 36.2%的个体中。至少在 1 个 SAB 试剂盒中未被代表的 4 个 eplet,发现于 12.9%的个体中。非中国个体比中国个体更有可能存在未被代表的 HLA 等位基因和 eplet。不同 SAB 测试试剂盒之间存在 HLA 等位基因和 eplet 代表的差异。使用补充 SAB 测试试剂盒可能会提高 HLA 等位基因和 eplet 的代表性。虽然一些 HLA 等位基因未被代表,但目前的 SAB 试剂盒中包含了大多数表位。然而,一些未被代表的等位基因可能包含可能产生无法检测到的抗体的表位。可能需要进一步研究来调查这些未被代表的等位基因和 eplet 的潜在临床影响,特别是在某些种族群体或高危人群中。